|
US5234814A
(en)
*
|
1989-06-01 |
1993-08-10 |
Du Pont Merck Pharmaceutical Company |
Diagnostic assay for alzheimer's disease
|
|
US5652214A
(en)
*
|
1989-06-05 |
1997-07-29 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US5093317A
(en)
*
|
1989-06-05 |
1992-03-03 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factor
|
|
US6693076B1
(en)
|
1989-06-05 |
2004-02-17 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US6723699B1
(en)
|
1989-06-05 |
2004-04-20 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
AU6909091A
(en)
*
|
1989-12-05 |
1991-06-26 |
Ramsey Foundation |
Neurologic agents for nasal administration to the brain
|
|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
|
US6407061B1
(en)
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
|
US5130129A
(en)
*
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
|
DE69222303T2
(de)
|
1991-04-30 |
1998-01-22 |
Eukarion Inc |
Kationisierte antikörper gegen intrazelluläre eiweisse
|
|
JP2930421B2
(ja)
*
|
1994-02-28 |
1999-08-03 |
メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング |
薬剤組成物、その製造方法及びその使用方法
|
|
US5639940A
(en)
|
1994-03-03 |
1997-06-17 |
Pharmaceutical Proteins Ltd. |
Production of fibrinogen in transgenic animals
|
|
US6709653B1
(en)
*
|
1994-09-16 |
2004-03-23 |
Human Genome Sciences, Inc. |
Antibodies specific for human inositol monophosphatase H1
|
|
GB9509620D0
(en)
|
1995-05-12 |
1995-07-05 |
Nat Blood Authority |
Transepithelial transport of molecular species
|
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US6172043B1
(en)
|
1997-01-10 |
2001-01-09 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
|
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
ES2345746T3
(es)
*
|
1998-05-21 |
2010-09-30 |
University Of Tennessee Research Foundation |
Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
|
|
US7273618B2
(en)
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
AUPQ180499A0
(en)
*
|
1999-07-23 |
1999-08-19 |
Biomolecular Research Institute Limited |
Beta-amyloid peptide inhibitors
|
|
EA006606B1
(ru)
*
|
2000-02-24 |
2006-02-24 |
Вашингтон Юниверсити |
Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
|
|
EP2226385B1
(de)
|
2000-09-13 |
2013-07-10 |
Novo Nordisk Health Care AG |
Varianten des menschlichen Koagulationsfaktors VII
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
WO2002035987A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Massachusetts Institute Of Technology |
METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
|
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
ES2432967T3
(es)
|
2001-03-22 |
2013-12-05 |
Novo Nordisk Health Care Ag |
Derivados del Factor VII de coagulación
|
|
US20020172676A1
(en)
*
|
2001-05-16 |
2002-11-21 |
George Jackowski |
Method of treatment of alzheimer's disease and device therefor
|
|
US7605177B2
(en)
|
2001-05-24 |
2009-10-20 |
Neuren Pharmaceuticals Limited |
Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
|
|
US7714020B2
(en)
|
2001-05-24 |
2010-05-11 |
Neuren Pharmaceuticals Limited |
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
|
|
EP1401808B1
(de)
|
2001-05-24 |
2009-07-08 |
Neuren Pharmaceuticals Limited |
Gpe-analoga und peptidomimetika
|
|
US20030096748A1
(en)
*
|
2001-06-04 |
2003-05-22 |
The Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
|
EP1944040B1
(de)
*
|
2001-08-17 |
2012-08-01 |
Washington University |
Assay-Verfahren für Alzheimer
|
|
US20030082191A1
(en)
*
|
2001-08-29 |
2003-05-01 |
Poduslo Joseph F. |
Treatment for central nervous system disorders
|
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7074893B2
(en)
*
|
2002-06-03 |
2006-07-11 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
|
|
ES2344645T3
(es)
|
2003-02-10 |
2010-09-02 |
Applied Molecular Evolution, Inc. |
Moleculas de union al abeta.
|
|
EP3103869A1
(de)
|
2003-03-18 |
2016-12-14 |
Novo Nordisk Health Care AG |
Verfahren zur herstellung von factor vii polypeptiden
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
CN101870729A
(zh)
|
2003-09-09 |
2010-10-27 |
诺和诺德医疗保健公司 |
凝固因子ⅶ多肽
|
|
DE602004027291D1
(de)
|
2003-11-25 |
2010-07-01 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
|
CA2559285A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
EP1838348B1
(de)
*
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
|
|
US20060257396A1
(en)
*
|
2004-12-15 |
2006-11-16 |
Jacobsen Jack S |
Abeta antibodies for use in improving cognition
|
|
ES2396555T3
(es)
*
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
|
ATE524489T1
(de)
|
2005-07-29 |
2011-09-15 |
Us Gov Health & Human Serv |
Mutierte pseudomonas-exotoxine mit reduzierter antigenität
|
|
US8124397B2
(en)
*
|
2005-08-08 |
2012-02-28 |
Oregon Health & Science University |
Inactivating pathogens with oxidizing agents for vaccine production
|
|
EP1957093B1
(de)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotektive und neurorestorative verfahren und zusammensetzungen
|
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
|
JP5690047B2
(ja)
|
2005-09-14 |
2015-03-25 |
ノボ ノルディスク ヘルス ケア アーゲー |
ヒト凝固第ｖｉｉ因子ポリペプチド
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
EP1973948B1
(de)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
|
AU2006331542A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
|
WO2007106536A2
(en)
|
2006-03-14 |
2007-09-20 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
EP4793360A2
(de)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
|
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
WO2007131133A2
(en)
|
2006-05-04 |
2007-11-15 |
Genentech, Inc. |
Methods and compositions relating to zpa polypeptides
|
|
NZ607881A
(en)
|
2006-07-14 |
2014-11-28 |
Genentech Inc |
Humanized antibody against amyloid beta
|
|
RU2498999C2
(ru)
|
2006-07-14 |
2013-11-20 |
Ац Иммуне Са |
Гуманизированное антитело к амилоиду бета
|
|
US8236313B2
(en)
|
2006-10-06 |
2012-08-07 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Prevention of tissue ischemia, related methods and compositions
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
WO2008088983A1
(en)
*
|
2007-01-18 |
2008-07-24 |
Eli Lilly And Company |
PEGYLATED Aβ FAB
|
|
WO2008100560A2
(en)
*
|
2007-02-14 |
2008-08-21 |
University Of Southern California |
Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
CA2678404C
(en)
|
2007-02-28 |
2019-03-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
US20090004213A1
(en)
*
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
|
WO2008131298A2
(en)
*
|
2007-04-18 |
2008-10-30 |
Elan Pharma International Limited |
Prevention and treatment of cerebral amyloid angiopathy
|
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
WO2008139480A2
(en)
*
|
2007-05-16 |
2008-11-20 |
Yeda Research And Development Co. Ltd. |
Assessment of blood-brain barrier disruption
|
|
CA2690434C
(en)
|
2007-06-12 |
2018-05-22 |
Ac Immune S.A. |
Monoclonal anti beta amyloid antibody
|
|
HRP20150086T1
(xx)
|
2007-06-12 |
2015-02-27 |
Ac Immune S.A. |
Humanizirana antitijela za beta amiloid
|
|
EP2008666A1
(de)
*
|
2007-06-29 |
2008-12-31 |
Institut Pasteur |
Verwendung von VHH-Antikörpern zur Herstellung von Peptidvektoren zur Verabreichung einer relevanten Substanz und Anwendungen der Peptidvektoren
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
DK2197903T3
(en)
*
|
2007-09-04 |
2015-01-05 |
Us Gov Health & Human Serv |
Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
EP3127921A1
(de)
*
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
|
|
AU2008311366B2
(en)
|
2007-10-05 |
2015-03-12 |
Ac Immune S.A. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
CN101514335B
(zh)
*
|
2008-02-22 |
2013-04-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
|
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
EP2143735A1
(de)
*
|
2008-07-10 |
2010-01-13 |
Institut Pasteur |
Variable Domänen von Schwerketten-Antikörpern, die sich gegen GFAPs richten
|
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
AU2009303526B2
(en)
|
2008-10-14 |
2015-01-15 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
CA2737597C
(en)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
|
CA2741089A1
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
AU2009313927A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Astrazeneca Ab |
Azaquinolinone derivatives and uses thereof
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US10167263B2
(en)
|
2008-11-20 |
2019-01-01 |
Northwestern University |
Treatment of amyotrophic lateral sclerosis
|
|
MX2011006870A
(es)
|
2008-12-23 |
2011-07-19 |
Genentech Inc |
Variantes de inmunoglobulina con union alterada a proteina a.
|
|
CA2749993C
(en)
*
|
2009-01-23 |
2016-12-20 |
Surmodics Pharmaceuticals, Inc. |
Continuous double emulsion process for making microparticles
|
|
CN101792745B
(zh)
|
2009-02-04 |
2014-09-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
|
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
|
CN108373509A
(zh)
|
2009-03-10 |
2018-08-07 |
贝勒研究院 |
靶向抗原呈递细胞的抗病毒疫苗
|
|
BRPI1009455A2
(pt)
|
2009-03-10 |
2016-03-01 |
Baylor Res Inst |
anticorpos anti-c40 e usos dos mesmos
|
|
BRPI1009454A2
(pt)
*
|
2009-03-10 |
2019-09-24 |
Baylor Res Institute |
vacinas contra o câncer direcionadas a células apresentadoras de antígenos
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
WO2010129665A2
(en)
|
2009-05-05 |
2010-11-11 |
Cambria Pharmaceuticals, Inc. |
Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
|
|
SG176628A1
(en)
|
2009-06-05 |
2012-01-30 |
Link Medicine Corp |
Aminopyrrolidinone derivatives and uses thereof
|
|
CA2767755C
(en)
|
2009-07-17 |
2021-10-12 |
Rigshospitalet |
Inhibitors of complement activation
|
|
WO2011021175A2
(en)
|
2009-08-18 |
2011-02-24 |
Ben Gurion University Of The Negev Research And Development Authority |
System and method for analyzing imaging data
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック， インコーポレイテッド |
突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
|
|
RU2012114005A
(ru)
|
2009-09-11 |
2013-10-20 |
Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез |
Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью
|
|
US9175070B2
(en)
|
2009-09-25 |
2015-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 and their use
|
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
|
SG10201406763WA
(en)
|
2009-10-22 |
2014-11-27 |
Genentech Inc |
Modulation of axon degeneration
|
|
US8961989B2
(en)
|
2009-11-20 |
2015-02-24 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
|
MX2012007379A
(es)
|
2009-12-23 |
2012-08-31 |
Genentech Inc |
Anticuerpos anti-bv8 y usos de los mismos.
|
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
|
EP2543730B1
(de)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Variante einer konstanten antikörperregion
|
|
AU2011222883B2
(en)
|
2010-03-05 |
2016-05-26 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
|
CN103068851B
(zh)
|
2010-06-16 |
2015-03-11 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
|
US9221900B2
(en)
|
2010-07-30 |
2015-12-29 |
Ac Immune S.A. |
Methods for identifying safe and functional humanized antibodies
|
|
WO2012020124A1
(en)
|
2010-08-12 |
2012-02-16 |
Ac Immune S.A. |
Vaccine engineering
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2012045882A2
(en)
|
2010-10-07 |
2012-04-12 |
Ac Immune S.A. |
Pharmaceutical composition
|
|
EP2632434B1
(de)
|
2010-10-26 |
2025-08-20 |
AC Immune S.A. |
Liposomenbasiertes konstrukt ein peptid enthaltend, das durch hydrophobe einheiten modifiziert ist
|
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
US20120301465A1
(en)
|
2011-03-25 |
2012-11-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Compositions and methods to immunize against hepatitis c virus
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
US9206257B2
(en)
|
2011-04-19 |
2015-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
EP2704739B1
(de)
|
2011-05-06 |
2017-07-12 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Gegen mesothelin gerichtetes rekombinantes immuntoxin
|
|
ES2667425T3
(es)
|
2011-06-10 |
2018-05-10 |
Oregon Health & Science University |
Glucoproteínas y vectores recombinantes de CMV
|
|
AU2012272815B2
(en)
|
2011-06-22 |
2017-09-07 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
HUE053664T2
(hu)
|
2011-07-18 |
2021-07-28 |
The United States Of America |
Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására
|
|
US20140348865A1
(en)
|
2011-09-12 |
2014-11-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. |
Immunogens based on an hiv-1 v1v2 site-of-vulnerability
|
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
ES2654160T3
(es)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anticuerpos de IgE anti-HMW-MAA
|
|
JP6358953B2
(ja)
|
2011-10-07 |
2018-07-18 |
エーシー イミューン エス．エー． |
タウを認識するホスホ特異的抗体
|
|
US10275680B2
(en)
|
2011-10-19 |
2019-04-30 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
|
PL2812024T3
(pl)
|
2012-02-09 |
2018-09-28 |
Var2 Pharmaceuticals Aps |
Celowanie glikanów siarczanu chondroityny
|
|
CN104271772A
(zh)
|
2012-03-29 |
2015-01-07 |
科罗拉多州立大学董事会,公司实体 |
点击核酸
|
|
CA2869438C
(en)
|
2012-04-05 |
2021-08-17 |
Ac Immune S.A. |
Humanized tau antibody
|
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
CA2874621A1
(en)
|
2012-05-22 |
2013-11-28 |
Genentech, Inc. |
N-substituted benzamides and their use in the treatment of pain
|
|
JP6267193B2
(ja)
|
2012-05-22 |
2018-01-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
置換ジピリジルアミン類及びそれらの使用
|
|
CN104520331B
(zh)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
|
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
|
US10071957B2
(en)
|
2012-07-06 |
2018-09-11 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
JP6211084B2
(ja)
|
2012-08-21 |
2017-10-11 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
ベンゾシクロオクチン化合物およびその使用
|
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
JP6262743B2
(ja)
|
2012-09-27 |
2018-01-17 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
置換スルホンアミド化合物
|
|
CN104704118A
(zh)
|
2012-10-15 |
2015-06-10 |
诺和诺德保健Ag（股份有限公司） |
凝血因子vii多肽
|
|
EP2908851A1
(de)
|
2012-10-19 |
2015-08-26 |
Bavarian Nordic Inc. |
Verfahren und zusammensetzungen zur krebsbehandlung
|
|
US9775895B2
(en)
|
2012-12-12 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV therapeutics and methods of making and using same
|
|
RU2681994C2
(ru)
|
2012-12-26 |
2019-03-14 |
Онкосинерджи, Инк. |
КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
MX2015009270A
(es)
|
2013-01-18 |
2015-10-30 |
Hoffmann La Roche |
Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
|
|
US9534041B2
(en)
|
2013-02-12 |
2017-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize a norovirus
|
|
CA2905418C
(en)
|
2013-03-13 |
2023-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
EP4421177A3
(de)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Rsv-f-prefusionsproteine und deren verwendung
|
|
CN105263490B
(zh)
|
2013-03-14 |
2018-05-22 |
基因泰克公司 |
取代的三唑并吡啶及其使用方法
|
|
MX374811B
(es)
|
2013-03-15 |
2025-03-06 |
Ac Immune Sa |
Anticuerpos anti-tau y métodos de uso.
|
|
EP2988668B1
(de)
|
2013-04-24 |
2019-07-24 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetresonanzkarten zur analyse von gewebe
|
|
RU2015147601A
(ru)
|
2013-05-01 |
2017-06-05 |
Ф. Хоффманн-Ля Рош Аг |
С-связанные гетероциклоалкилзамещенные пиримидины и их применения
|
|
TWI710558B
(zh)
|
2013-05-01 |
2020-11-21 |
瑞士商赫孚孟拉羅股份公司 |
二雜芳基化合物及其用途
|
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
|
EP3583950A1
(de)
|
2013-05-09 |
2019-12-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
|
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
|
CA2917919C
(en)
|
2013-07-09 |
2019-07-02 |
Duke University |
Certain improved human bispecific egfrviii antibody engaging molecules
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP3041484B1
(de)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
|
|
US11465978B2
(en)
|
2013-09-11 |
2022-10-11 |
The Administrators Of The Tulane Educational Fund |
Anthranilic amides and the use thereof
|
|
EP3046588B1
(de)
|
2013-09-17 |
2022-03-02 |
OBI Pharma, Inc. |
Zusammensetzungen aus einem kohlenhydratimpfstoff zur induktion von immunreaktionen und verwendungen davon bei der krebsbehandlung
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
DK3055302T3
(en)
|
2013-10-11 |
2019-03-18 |
Hoffmann La Roche |
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
|
|
EP3054987B1
(de)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem-8-antikörper und deren verwendung
|
|
EP3062808B1
(de)
|
2013-10-28 |
2021-09-29 |
The Regents of the University of California |
Behandlung von metastasierendem prostatakrebs
|
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
|
US9931393B2
(en)
|
2013-12-20 |
2018-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogenic JC polyomavirus compositions and methods of use
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
US10398772B2
(en)
|
2014-01-08 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
|
|
WO2015106281A1
(en)
|
2014-01-13 |
2015-07-16 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
|
AU2015206515B2
(en)
|
2014-01-15 |
2019-12-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cartilage targeting agents and their use
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
|
WO2015175704A1
(en)
|
2014-05-14 |
2015-11-19 |
The Regents Of The University Of California |
Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
|
|
EP4116329A1
(de)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2-glykoantikörper und verwendungen davon
|
|
KR20170010003A
(ko)
|
2014-05-27 |
2017-01-25 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
抗ｃｄ２０糖操作抗体群およびその使用
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
JP7063538B2
(ja)
|
2014-05-28 |
2022-05-09 |
アカデミア シニカ |
抗ＴＮＦα糖操作抗体群およびその使用
|
|
CN106715418A
(zh)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
治疗化合物及其使用方法
|
|
US9683017B2
(en)
|
2014-07-17 |
2017-06-20 |
University Tennessee Research Foundation |
Inhibitory peptides of viral infection
|
|
EP3177320B1
(de)
|
2014-07-31 |
2021-01-06 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Humane monoklonale antikörper gegen epha4 und deren verwendung
|
|
US10213506B2
(en)
|
2014-08-26 |
2019-02-26 |
University Of Tennessee Research Foundation |
Targeting immunotherapy for amyloidosis
|
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
|
EP3191500A4
(de)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
PL3590962T3
(pl)
|
2014-10-23 |
2022-01-31 |
Singh Molecular Medicine, Llc |
Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
|
|
US20170267784A1
(en)
|
2014-10-23 |
2017-09-21 |
Singh Molecular Medicine, Llc |
Single domain antibodies directed against intracellular antigens
|
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
|
EP3221349B1
(de)
|
2014-11-19 |
2020-11-04 |
Axon Neuroscience SE |
Humanisierte tau-antikörper bei alzheimer-krankheit
|
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
US10420834B2
(en)
|
2014-12-24 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus F proteins and their use
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
CN114702581B
(zh)
|
2015-01-30 |
2025-08-01 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
TWI759261B
(zh)
|
2015-02-27 |
2022-04-01 |
日商中外製藥股份有限公司 |
Ｉｌ－６受體抗體用於製備醫藥組成物的用途
|
|
JP6701225B2
(ja)
|
2015-03-09 |
2020-05-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
三環式ｄｌｋ阻害剤及びその使用
|
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
|
HRP20200583T1
(hr)
|
2015-03-20 |
2020-07-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protutijela koja neutraliziraju gp120 i njihova upotreba
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
MA42118A
(fr)
|
2015-05-22 |
2018-03-28 |
Genentech Inc |
Benzamides substitués et leurs méthodes d'utilisation
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CA3172801A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
WO2017035271A1
(en)
|
2015-08-27 |
2017-03-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
|
JP2018531625A
(ja)
*
|
2015-09-11 |
2018-11-01 |
ナセント バイオテック インコーポレイテッド |
脳への向上した薬物送達の方法
|
|
EP4477269A3
(de)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Für fibroblastenwachstumsfaktor-rezeptor 4 (fgfr4) spezifische monoklonale antikörper und verfahren zu deren verwendung
|
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
ES2778651T3
(es)
|
2015-10-09 |
2020-08-11 |
Miltenyi Biotec Technology Inc |
Receptores de antígeno quimérico y métodos de uso
|
|
TWI746473B
(zh)
|
2015-11-02 |
2021-11-21 |
美商辛分子醫藥有限公司 |
針對細胞內抗原之單域抗體
|
|
EP4011911A1
(de)
|
2015-11-03 |
2022-06-15 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Neutralisierende antikörper gegen hiv-1 gp41 und deren verwendung
|
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
EP3394098A4
(de)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin-antikörper und verfahren zur verwendung
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
|
EP3431102A4
(de)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
Zellschadeninduzierendes therapeutisches arzneimittel zur verwendung in der krebstherapie
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
US10766858B2
(en)
|
2016-03-30 |
2020-09-08 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
IL262296B2
(en)
|
2016-04-22 |
2024-09-01 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
|
AU2017255077B2
(en)
|
2016-04-28 |
2024-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
US11141475B2
(en)
|
2016-05-10 |
2021-10-12 |
Najit Technologies, Inc. |
Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
EP3487849A1
(de)
|
2016-07-20 |
2019-05-29 |
H. Hoffnabb-La Roche Ag |
Sulfonylcycloalkylcarboxamidverbindungen als trpa1-modulatoren
|
|
CN109476640B
(zh)
|
2016-07-20 |
2022-02-25 |
豪夫迈·罗氏有限公司 |
双环脯氨酸化合物
|
|
KR20190067765A
(ko)
|
2016-07-27 |
2019-06-17 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
CN109803964A
(zh)
|
2016-08-12 |
2019-05-24 |
豪夫迈·罗氏有限公司 |
磺酰基吡啶基trp抑制剂
|
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
CN117298260A
(zh)
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
US10702589B2
(en)
|
2016-10-04 |
2020-07-07 |
Ann And Robert H. Lurie Children's Hospital Of Chicago |
Compositions and methods of treating neurological disorder and stress-induced conditions
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
JP7349359B2
(ja)
|
2016-10-17 |
2023-09-22 |
エフ． ホフマン－ラ ロシュ アーゲー |
二環式ピリドンラクタム及びその使用方法。
|
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
JP7171567B2
(ja)
|
2016-11-28 |
2022-11-15 |
エフ．ホフマン－ラ ロシュ アーゲー |
一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
|
|
US11071721B2
(en)
|
2016-12-02 |
2021-07-27 |
Genentech, Inc. |
Bicyclic amide compounds and methods of use thereof
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
EP3559038B1
(de)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Menschliche antikörper spezifisch für flt3 und deren verwendungen
|
|
CN110603265B
(zh)
|
2017-01-09 |
2024-01-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
EP3580235B1
(de)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
|
|
JP7178357B2
(ja)
|
2017-03-07 |
2022-11-25 |
エフ．ホフマン－ラ ロシュ アーゲー |
オキサジアゾール一過性受容器電位チャネル阻害剤
|
|
AU2018240556B2
(en)
|
2017-03-24 |
2025-02-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
|
EP3601273B1
(de)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamid-derivate als natriumkanalinhibitoren
|
|
KR20190130621A
(ko)
|
2017-03-31 |
2019-11-22 |
시애틀 지네틱스, 인크. |
Chk1 저해제와 wee1 저해제의 조합물
|
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
|
|
EP3615067A1
(de)
|
2017-04-28 |
2020-03-04 |
Seattle Genetics, Inc. |
Behandlung von her2-positivem krebs
|
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
CN119613408A
(zh)
|
2017-07-14 |
2025-03-14 |
豪夫迈·罗氏有限公司 |
二环酮化合物及其使用方法
|
|
AU2018309735B2
(en)
|
2017-07-31 |
2025-03-13 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
GB201712952D0
(en)
|
2017-08-11 |
2017-09-27 |
Univ Edinburgh |
Immunomodulatory agent
|
|
JP7035170B2
(ja)
|
2017-09-15 |
2022-03-14 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
WO2019072942A1
(en)
|
2017-10-11 |
2019-04-18 |
F. Hoffmann-La Roche Ag |
BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
|
|
EP4279584A3
(de)
|
2017-10-16 |
2024-03-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd22-immuntherapie
|
|
MX2020003451A
(es)
|
2017-10-31 |
2020-08-03 |
Hoffmann La Roche |
Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
|
|
KR20260090008A
(ko)
|
2017-11-01 |
2026-06-16 |
추가이 세이야쿠 가부시키가이샤 |
생물 활성이 저하된 항체 배리언트 및 아이소폼
|
|
CN117756946A
(zh)
|
2017-11-03 |
2024-03-26 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
US11235046B2
(en)
|
2017-11-04 |
2022-02-01 |
Nevada Research & Innovation Corporation |
Immunogenic conjugates and methods of use thereof
|
|
JP7235748B2
(ja)
|
2017-11-30 |
2023-03-08 |
ハンミ ファーム．カンパニー リミテッド |
４－アミノ－ｎ－（１－（（３－クロロ－２－フルオロフェニル）アミノ）－６－メチルイソキノリン－５－イル）チエノ［３，２－ｄ］ピリミジン－７－カルボキサミドの塩とその結晶形態
|
|
JP7377802B2
(ja)
|
2017-12-20 |
2023-11-10 |
レンティジェン・テクノロジー・インコーポレイテッド |
免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
|
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
TW202000201A
(zh)
|
2018-02-20 |
2020-01-01 |
瑞士商赫孚孟拉羅股份公司 |
製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
|
|
CN111971299A
(zh)
|
2018-02-21 |
2020-11-20 |
美国政府(由卫生和人类服务部的部长所代表) |
HIV-1 Env的中和抗体及其用途
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
|
WO2019191702A1
(en)
|
2018-03-30 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
Substituted hydro-pyrido-azines as sodium channel inhibitors
|
|
EP3781571B1
(de)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds)
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
EP3802616A4
(de)
|
2018-06-04 |
2022-03-30 |
University of Maryland, Baltimore |
Verfahren zur prävention einer akuten nierenläsion
|
|
TW202504930A
(zh)
|
2018-06-27 |
2025-02-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
|
|
CN112789504A
(zh)
|
2018-07-13 |
2021-05-11 |
瓦克特诊断有限责任公司 |
使用重组疟疾蛋白var2csa分离胎儿来源的循环细胞
|
|
CA3106544A1
(en)
|
2018-08-08 |
2020-02-13 |
Mitchell Ho |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
AU2019343184B2
(en)
|
2018-09-20 |
2026-04-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
WO2020069184A2
(en)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
US12365722B2
(en)
|
2018-10-19 |
2025-07-22 |
University Of Maryland, College Park |
Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
|
|
AU2019387377B2
(en)
|
2018-11-30 |
2026-07-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
|
CA3120324A1
(en)
|
2018-12-04 |
2020-06-11 |
The Rockefeller University |
Hiv vaccine immunogens
|
|
EP3883609A2
(de)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Glykoprotein-spezifische monoklonale antikörper des ebola-virus und deren verwendungen
|
|
AU2020206308B2
(en)
|
2019-01-08 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
CN113302193B
(zh)
|
2019-01-11 |
2026-05-29 |
豪夫迈·罗氏有限公司 |
双环吡咯并三唑酮化合物及其使用方法
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
TW202042820A
(zh)
|
2019-01-28 |
2020-12-01 |
美商西雅圖遺傳學股份有限公司 |
以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
|
|
AU2020232789B2
(en)
|
2019-03-06 |
2026-04-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
|
KR20220086627A
(ko)
|
2019-10-21 |
2022-06-23 |
시아겐 인크. |
카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
EP4058435A1
(de)
|
2019-11-13 |
2022-09-21 |
Genentech, Inc. |
Therapeutische verbindungen und verfahren zur verwendung
|
|
CA3159770A1
(en)
|
2019-11-15 |
2021-05-20 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
|
|
EP4061351A4
(de)
|
2019-11-18 |
2023-12-20 |
The Regents of the University of California |
Doppelte androgenrezeptor/akr1c3-inhibitoren
|
|
MX2022006676A
(es)
|
2019-12-04 |
2022-07-05 |
Ac Immune Sa |
Nuevas moleculas para terapia y diagnostico.
|
|
EP4041769A1
(de)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antikörper-wirkstoff-konjugate spezifisch für cd276 und deren verwendungen
|
|
US12503695B2
(en)
|
2020-01-27 |
2025-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
|
|
WO2021168292A1
(en)
|
2020-02-20 |
2021-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
|
US20230136203A1
(en)
|
2020-03-11 |
2023-05-04 |
Seagen Inc. |
Methods of treating her2 mutant cancers with tucatinib
|
|
EP4168437A1
(de)
|
2020-06-22 |
2023-04-26 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit tslpr-cd19- oder tslpr-cd22-immuntherapie
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN116615452A
(zh)
|
2020-08-14 |
2023-08-18 |
Ac免疫有限公司 |
人源化抗tdp-43结合分子及其用途
|
|
IL301405A
(en)
|
2020-09-28 |
2023-05-01 |
Seagen Inc |
Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
|
|
AU2021353532A1
(en)
|
2020-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Process for the preparation of biheteroaryl compounds and crystal forms thereof
|
|
WO2022079297A1
(en)
|
2020-10-16 |
2022-04-21 |
Ac Immune Sa |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CN116801898A
(zh)
|
2020-11-05 |
2023-09-22 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
MX2023005528A
(es)
|
2020-11-17 |
2023-06-23 |
Seagen Inc |
Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1.
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
WO2022172085A2
(en)
|
2021-02-15 |
2022-08-18 |
Takeda Pharmaceutical Company Limited |
Cell therapy compositions and methods for modulating tgf-b signaling
|
|
WO2022187440A1
(en)
|
2021-03-03 |
2022-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
La protien as a novel regulator of osteoclastogenesis
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
|
US20240417446A1
(en)
|
2021-10-26 |
2024-12-19 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
US11492394B1
(en)
|
2021-10-29 |
2022-11-08 |
Nascent Biotech, Inc. |
Kits and containers for treating vimentin expressing tumors
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
US12110276B2
(en)
|
2021-11-24 |
2024-10-08 |
Genentech, Inc. |
Pyrazolo compounds and methods of use thereof
|
|
AU2023221539A1
(en)
|
2022-02-16 |
2024-08-22 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
CN119213128A
(zh)
|
2022-03-09 |
2024-12-27 |
株式会社丘阿德 |
与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
|
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN115806618B
(zh)
|
2022-03-30 |
2025-11-11 |
河北森朗生物科技有限公司 |
一种抗cd7的纳米抗体vhh12及其相关产品、方法和用途
|
|
IL316153A
(en)
|
2022-04-08 |
2024-12-01 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
|
US20250333484A1
(en)
|
2022-04-14 |
2025-10-30 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to ebola virus glycoprotein and their use
|
|
WO2023230429A1
(en)
|
2022-05-22 |
2023-11-30 |
Seagen Inc. |
Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
|
|
CN119923410A
(zh)
|
2022-07-28 |
2025-05-02 |
莱蒂恩技术公司 |
用于治疗实体瘤的嵌合抗原受体治疗
|
|
EP4565329A1
(de)
|
2022-08-01 |
2025-06-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
An die unterseite der viralen influenza-neuraminidase bindende monoklonale antikörper
|
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
WO2024138151A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
WO2024184494A1
(en)
|
2023-03-08 |
2024-09-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
AU2025218272A1
(en)
|
2024-02-07 |
2026-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025194126A1
(en)
|
2024-03-15 |
2025-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency
|
|
WO2025212999A1
(en)
|
2024-04-05 |
2025-10-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent fgfr4-targeted antibody-drug conjugates and their use for treating cancers expressing fgfr4
|
|
WO2025221781A2
(en)
|
2024-04-15 |
2025-10-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
|
|
WO2025235598A1
(en)
|
2024-05-09 |
2025-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
|
|
WO2025240496A1
(en)
|
2024-05-14 |
2025-11-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors
|
|
US20260000765A1
(en)
|
2024-06-27 |
2026-01-01 |
Lentigen Technology, Inc. |
CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
|
|
WO2026013218A1
(en)
|
2024-07-10 |
2026-01-15 |
Ac Immune Sa |
Anti-tdp-43 vectors, binding molecules and uses thereof
|
|
WO2026122978A1
(en)
|
2024-12-06 |
2026-06-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Linker for antibody-drug conjugates and antibody-drug conjugates comprising the linker
|
|
WO2026128545A1
(en)
|
2024-12-11 |
2026-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin-targeted car t cells with increased anti-tumor efficacy, persistence and resilience and use thereof for the treatment of mesothelin-positive cancers
|